Dkt. #1031-PCT-US



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Anders OEHRVIK and Staffan ERIKSSON

U.S. Serial No.: Not Yet Known, corresponding to

International Application No. PCT/EP2003/007547, filed July 11, 2003, which claims priority of E.P. Serial No.

02017004.9, filed July 27, 2002

Filed Date : January 26, 2005

For : METHOD FOR DETERMINATION OF THYMIDINE

KINASE 1 ACTIVITY AND THE USE THEREOF

Law Offices of Albert Wai-Kit Chan, LLC

World Plaza, Suite 604 141-07 20<sup>th</sup> Avenue Whitestone, NY 11357

January 26, 2005

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Mail Stop Patent Application

Sir/Madam:

## INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, Applicants would like to direct the Examiner's attention to the following references which are listed below and on Forms PTO/SB/08A and PTO/SB/08B (which are attached hereto as **Exhibit A**), and each individual reference further attached as **Exhibits 1** through **6**.

- PCT International Search Report for Anders OEHRVIK and Staffan ERIKSSON, Int'l Application No. PCT/EP2003/007547, Filed July 11, 2003, Dated November 13, 2003. [Exhibit 1]
- 2. International Publication Number WO 95/04758 A1 for BRIGHAM YOUNG UNIVERSITY TECHNOLOGY TRANSFER OFFICE, Published February 16, 1995. "Monoclonal Antibodies to Thymidine Kinase Isozymes". [Exhibit 2]

Applicant(s)
U.S. Serial No.:
Filed :

Anders OEHRVIK and Staffan (
Not Yet Known
Herewith

DT12 Rec'd PCT/PTO 2 6 JAN 2005

Page :

3. International Publication Number E.P. 0094923 A2 for GRONOWITZ, et al., Published November 23, 1983. "A Method of Determining dTk Isoenzyme Activity and the Use Thereof". [Exhibit 3]

- 4. GOUJON, et al.; "Monitoring of Intracellular Levels of 5'-monophosphate-AZT Using an Enzyme Immunoassay", Journal of Immunological Methods, Elsevier Science Publishers B.V., Amsterdam, NL; Vol. 218, No. 1-2, September 1, 1998, Pgs. 19-30, XP004146529. [Exhibit 4]
- 5. KUROIWA, et al.; "Specific Recognition of Cytosolic Thymidine Kinase in the Human Lung Tumor by Monoclonal Antibodies Raised Against Recombinant Human Thymidine Kinase", Journal of Immunological Methods, Elsevier Science Publishers B.V., Amsterdam, NL; Vol. 253, No. 1-2, July 1, 2001, Pages 1-11, XP004241355. [Exhibit 5]
- 6. D'CRUZ, et al.; "Thymidine Kinase-Independent Intracellular Delivery of Bioactive Nucleotides by Aryl Phosphate Derivatives of Bromo-methoxy Zidovudine (Compounds WHI-05 and WHI-07) in Normal Human Female Genital Tract Epithelial Cells and Sperm", Database Biosis 'Online! Biosciences Information Service, Philadelphia, PA, US; Vol. 64, No. 1, January 2001, Pages 51-59, XP002225459. [Exhibit 6]

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this IDS. However, if any fee is required, authorization is hereby given

Applicant(s) U.S. Serial No. Anders OEHRVIK and Staffan Not Yet Known

KSSON

Filed

Herewith

DT12 Rec'd PCT/PTO 2 6 JAN 2005

Page 3

to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,

albert Wai Kit Cha

Albert Wai-Kit Chan Registration No. 36,479 Attorney for Applicants Law Offices of Albert Wai-Kit Chan, LLC World Plaza, Suite 604 141-07 20<sup>th</sup> Avenue

Whitestone, New York 11357 Tel: (718) 357-8836 Fax: (718) 357-8615

e-mail: kitchanlaw@aol.com

PTO/SB/08A (02-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Not Yet Known Filing Date Herewith First Named Inventor OEHRVIK, Anders Art Unit Not Yet Known Examiner Name Not Yet Known

Sheet 1 of 2 1031-PCT-US U. S. PATENT DOCUMENTS Examiner Document Number Publication Date Name of Patentee or Pages, Columns, Lines, Where MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Number-Kind Code<sup>2 (d known)</sup> Figures Appear US-US-US US US-US-US-US-US-TIS US-US-US-US-US-US-US-US-US-

**Application Number** 

Attorney Docket Number

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	MENTS  Name of Patentee or  Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Т
	2	WO 95/04758 A1	02-16-1995	BRIGHAM YOUNG UNIVERSITY		
	3	E.P. 0094923 A2	11-23-1983	GRONOWITZ, et al.		
						L
						┢
						┡

	<u> </u>			
Examiner Signature		Date Considered	···	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

'd PCT/PTO 26 JAN 2005

PTO/SB/08B (02-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO			re required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known			
,			Application Number	Not Yet Known		
INFORMAT	ION DIS	CLOSURE	Filing Date	Herewith		
STATEMENT BY APPLICANT			First Named Inventor	OEHRVIK, Anders		
(lise as m.	any sheets as n	eressan/l	Art Unit	Not Yet Known		
(ese as many shoets as meessary)			Examiner Name	Not Yet Known		
Sheet 2	of	2	Attorney Docket Number	1031-PCT-US		

Examiner	Cite	OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	PCT International Search Report for Anders OEHRVIK and Staffan ERIKSSON, Int'l Application No. PCT/EP2003/007547, Filed July 11, 2003, Dated November 13, 2003.	
	4	GOUJON, et al.; "Monitoring of Intracellular Levels of 5'-monophosphate-AZT Using an Enzyme Immunoassay", Journal of Immunological Methods, Elsevier Science Publishers B.V., Amsterdam, NL; Vol. 218, No. 1-2, September 1, 1998, Pgs. 19-30, XP004146529.	
	5	KUROIWA, et al.; "Specific Recognition of Cytosolic Thymidine Kinase in the Human Lung Tumor by Monoclonal Antibodies Raised Against Recombinant Human Thymidine Kinase", Journal of Immunological Methods, Elsevier Science Publishers B.V., Amsterdam, NL; Vol. 253, No. 1-2, July 1, 2001, Pages 1-11, XP004241355.	
	6	D'CRUZ, et al.; "Thymidine Kinase-Independent Intracellular Delivery of Bioactive Nucleotides by Aryl Phosphate Derivatives of Bromo-methoxy Zidovudine (Compounds WHI-05 and WHI-07) in Normal Human Female Genital Tract Epithelial Cells and Sperm", Database Biosis 'Online! Biosciences Information Service, Philadelphia, PA, US; Vol. 64, No. 1, January 2001, Pages 51-59, XP002225459.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.